Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Want to see DNTH full AI Analyst Report?
Top Page
Dianthus Therapeutics
(NASDAQ:DNTH)
Select Model
Select Model
Rating:61Neutral
Price Target:
$95.00
▲(1.87% Upside)
Action:Reiterated
Date:05/23/26
The score is held back primarily by weak financial performance (deep losses and ongoing cash burn), partially offset by a strong balance sheet and supportive corporate updates that enhance runway and trial execution. Technicals are favorable, while valuation is constrained by negative earnings and no dividend.
Positive Factors
Strong cash runway & liquidity
A pro forma cash position (~$1.2B) and recent equity financing materially extend runway, allowing Dianthus to fund multiple late-stage programs and parallel trials through 2028–2030. This durable liquidity reduces near-term financing pressure and supports execution of registrational studies and portfolio strategy.
Negative Factors
Persistent negative cash flow
Operating and free cash flows remain consistently negative and cash burn rose materially, creating a structural funding need over time. Even with current liquidity, sustained negative cash generation means the company remains dependent on capital markets or partnerships if programs extend or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway & liquidity
A pro forma cash position (~$1.2B) and recent equity financing materially extend runway, allowing Dianthus to fund multiple late-stage programs and parallel trials through 2028–2030. This durable liquidity reduces near-term financing pressure and supports execution of registrational studies and portfolio strategy.
Read all positive factors
Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.44B
Dividend YieldN/A
Average Volume (3M)1.00M
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth-79.52%
EPS Growth-43.40%
CountryUS
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.44K
Enterprise Value/Gross Profit2.58K
Enterprise Value/Ebitda-17.38
Forecast
1Y Price Target
$123.83Price Target Upside32.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$1.18M
Dianthus Therapeutics Business Overview & Revenue Model
Company Description
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and i...
How the Company Makes Money
Dianthus Therapeutics does not appear to generate meaningful recurring revenue from product sales because its programs are in clinical development and it has no approved products. As a result, its operations are primarily funded through financing ...
Dianthus Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.34M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| Gross Profit | 1.26M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| EBITDA | -187.38M | -177.93M | -101.45M | -47.82M | -29.56M | -13.09M |
| Net Income | -11.32M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11B | 404.30M | 275.24M | 173.72M | 75.49M | 176.93M |
| Total Debt | 1.36M | 1.39M | 1.49M | 585.00K | 788.00K | 0.00 |
| Total Liabilities | 45.57M | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M |
| Stockholders Equity | 1.20B | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M |
Cash Flow | ||||||
| Free Cash Flow | -130.49M | -129.27M | -78.28M | -36.97M | -29.21M | -60.80M |
| Operating Cash Flow | -130.29M | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M |
| Investing Cash Flow | -271.60M | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M |
| Financing Cash Flow | 1.02B | 280.13M | 255.62M | 133.57M | 96.68M | 89.60M |
Dianthus Therapeutics Technical Analysis
Neutral
93.26
Price Trends
87.37
Negative
73.45
Positive
55.19
Positive
Market Momentum
-0.89
Positive
42.04
Neutral
13.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Neutral. The current price of 93.26 is above the 20-day moving average (MA) of 86.19, above the 50-day MA of 87.37, and above the 200-day MA of 55.19, indicating a neutral trend. The MACD of -0.89 indicates Positive momentum. The RSI at 42.04 is Neutral, neither overbought nor oversold. The STOCH value of 13.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DNTH.
Dianthus Therapeutics Risk Analysis
Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dianthus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $3.75B | -21.20 | -32.55% | ― | ― | -7.28% | |
61 Neutral | $4.44B | -344.54 | -1.78% | ― | -79.52% | -43.40% | |
59 Neutral | $1.37B | -23.46 | -38.11% | ― | 18.24% | -5.21% | |
52 Neutral | $1.48B | ― | -55.68% | ― | ― | 51.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $823.90M | -7.40 | -11.85% | ― | 47.10% | -35.51% | |
45 Neutral | $1.67B | -2.53 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
DNTH
Dianthus Therapeutics
81.22
63.03
346.51%
ARDX
Ardelyx
5.54
1.78
47.34%
EWTX
Edgewise Therapeutics
34.84
19.58
128.31%
JANX
Janux Therapeutics Inc
13.51
-12.43
-47.92%
AMLX
Amylyx Pharmaceuticals Inc
13.01
7.57
139.15%
BHVN
Biohaven Ltd.
11.12
-5.95
-34.86%
Dianthus Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Dianthus Therapeutics Stockholders Reaffirm Board and Governance Structure
Positive
May 22, 2026
On May 21, 2026, Dianthus Therapeutics held its Annual Meeting of Stockholders, where investors elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting, reaffirming the companyR...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Dianthus Highlights Strong Cash Runway and Streamlined Trials
Positive
Mar 26, 2026
On March 26, 2026, Dianthus Therapeutics posted an updated corporate presentation outlining progress on its autoimmune pipeline and financial position. The company reported pro forma cash of about $1.2 billion, providing runway into 2030 to advanc...
Private Placements and FinancingRegulatory Filings and Compliance
Dianthus Therapeutics Announces Major Public Equity Offering
Positive
Mar 12, 2026
On March 10, 2026, Dianthus Therapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to launch a public offering of 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants equivalent to 40...
Business Operations and StrategyFinancial Disclosures
Dianthus Advances Claseprubart With Positive Phase 3 Update
Positive
Mar 9, 2026
On March 9, 2026, Dianthus Therapeutics reported fourth-quarter and full-year 2025 results and highlighted an early GO decision in its Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, after meeting resp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.